Biotech Blog Archives: Guest Content
next page ·
26 February 2008
Generic Biologics: How to Compete
Guest content from John Avellanet, managing director and principal of Cerulean Associates:
Follow-on biologics are a foregone conclusion in the US. Too much money is at stake. The more difficult discussion starts with how to prepare your company to compete.
Science Succumbs to Dollars
The financial pull on reimbursement organizations and the constituent push on [...]
continue reading... » One Comment
10 December 2007
FDA Enforcement Trends: 2007-2008
Guest content from John Avellanet, managing director of Cerulean Associates:
The US Food and Drug Administration (FDA) intends to increase regulatory enforcement, extending the recent trend of laboratory and clinical site inspections to unapproved drugs and reformulations. How can you avoid compliance trouble?
At the Food and Drug Law Institute’s 5th Annual Enforcement and Litigation conference, [...]
continue reading... » One Comment
26 July 2007
Expanding the bandwidth of life science investments: Increasing investment viability
Guest content Contributed by Jayme Norrie, Chief Strategic Officer, Incite World
From what we have experienced, angel investors are shoring up the gap in new innovations coming forward. However, they seem to be more naive than VC’s in terms of due diligence prior to investing. Scientists from the company march in with charts and scientific graphs [...]
continue reading... » 2 Comments
23 July 2007
Offshoring and U.S. Biotech Labor Shortages
Contributed by Agnes Shanley, Editor in Chief, Pharmaceutical Manufacturing
Every day we read about severe shortages of skilled biotech workers in the U.S.. At the same time, the trend to pharma offshoring and outsourcing is becoming more pronounced, and is moving from traditional pharma to biopharma.
We recently touched on some of these issues in Pharmaceutical Manufacturing. [...]
continue reading... » 2 Comments
19 July 2007
`Til Death Do Us Part, But First, the Pre-Nup: Why CAPA Needs to Evolve
A guest editorial from Emil Ciurczak, Contributing Editor, PharmaManufacturing.com
While reading a trade magazine recently, I was struck with the detailed information on how to design and implement a Corrective and Preventive Action (CAPA) system. ISO 9001:200, Clause 8.5.2 states, “…the organization shall take action to eliminate the cause of nonconformities encountered…” For medical devices, 21 [...]
continue reading... » 5 Comments
10 July 2007
Spread your message with BiotechBlog
BiotechBlog is syndicated by BlogBurst, which means that posts are syndicated to outlets such as Reuters, Biospace, San Francisco Gate, and dozens of other media outlets.
Post your content on BiotechBlog and have it syndicated across the web. To create a dialogue for important issues in biotechnology, BiotechBlog is adopting an open architecture. All user accounts [...]
